Crayne CB, et al. - Investigators assessed the effectiveness and safety of three treatments [ie, a second intravenous immunoglobulin (IVIg) infusion, methylprednisolone (IVMP), and infliximab (IFX)] in 388 individuals with refractory KD from the eight studies. Fever resolution was similar between IVIg and IVMP. This combined analysis was defined because of variability in design and data reporting methods among the studies and the risk of bias. In the absence of a clinical trial, in people who fail to react to initial IVIg, IFX monotherapy as second-line treatment should be taken into consideration. The result was based on a systematic review of the literature with pooled outcome data analysis implying that in comparison with a second IVIg dose and IVMP, in fever resolution, IFX is more efficient.